#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16458	16S	1529	1529	100.0	16S.l15.c17.ctg.1	2567	789.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1612	1612	C	1101	C	1101	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27796	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3993	866.9	0	.	n	.	0	T695C	SNP	695	695	T	1197	1197	C	1031	C,A	1029,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27796	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3993	866.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1839	1839	A	1156	A	1156	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27796	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3993	866.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2473	2473	C	933	C,T,G,A	929,1,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27796	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3993	866.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3099	3099	T	1003	T,C,A	783,219,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27796	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3993	866.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2547	2547	A	837	A	837	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2392	folP	852	852	100.0	folP.l6.c4.ctg.1	2013	148.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1254	1256	AGC	280;281;279	A;G,C;C	280;280,1;279	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5370	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3841	174.4	1	SNP	p	S91F	0	.	.	271	273	TCC	863	865	TCC	211;210;209	T;C;C,A	211;210;208,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5370	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3841	174.4	1	SNP	p	D95G	0	.	.	283	285	GAC	875	877	GAC	214;219;222	G,C;A;C	213,1;219;222	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5370	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3841	174.4	1	SNP	p	D95N	0	.	.	283	285	GAC	875	877	GAC	214;219;222	G,C;A;C	213,1;219;222	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	2130	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1717	154.6	1	SNP	p	G45D	1	.	.	133	135	GAC	675	677	GAC	258;260;258	G;A;C	258;260;258	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1184	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1337	110.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	5448	parC	2304	2304	99.96	parC.l15.c4.ctg.1	3329	203.9	0	.	p	.	0	M307I	NONSYN	919	921	ATG	1433	1435	ATA	241;244;243	A;T,A;A	241;243,1;243	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	5448	parC	2304	2304	99.96	parC.l15.c4.ctg.1	3329	203.9	1	SNP	p	D86N	0	.	.	256	258	GAC	770	772	GAC	227;223;221	G;A,C;C	227;221,2;221	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	5448	parC	2304	2304	99.96	parC.l15.c4.ctg.1	3329	203.9	1	SNP	p	S87R	0	.	.	259	261	AGT	773	775	AGT	219;218;218	A;G;T	219;218;218	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	5448	parC	2304	2304	99.96	parC.l15.c4.ctg.1	3329	203.9	1	SNP	p	S87W	0	.	.	259	261	AGT	773	775	AGT	219;218;218	A;G;T	219;218;218	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	5448	parC	2304	2304	99.96	parC.l15.c4.ctg.1	3329	203.9	1	SNP	p	S87I	0	.	.	259	261	AGT	773	775	AGT	219;218;218	A;G;T	219;218;218	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	5448	parC	2304	2304	99.96	parC.l15.c4.ctg.1	3329	203.9	1	SNP	p	S88P	0	.	.	262	264	TCC	776	778	TCC	220;221;225	T;C;C,A	220;221;224,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4538	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3163	178.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1790	1792	GGC	239;237;234	G,A;G;C	238,1;237;234	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1456	1458	GCA	239;242;244	G,A;C;A	238,1;242;244	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1459	1461	ATC	245;246;246	A,C;T;C	244,1;246;246	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1471	1473	GTG	254;259;260	G;T,G;G	254;258,1;260	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1471	1473	GTG	254;259;260	G;T,G;G	254;258,1;260	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1975	1977	ACC	244;243;245	A;C;C	244;243;245	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2029	2031	GCG	240;240;239	G;C;G	240;240;239	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2029	2031	GCG	240;240;239	G;C;G	240;240;239	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2152	2154	GGC	219;219;220	G;G;C	219;219;220	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2161	2163	GGC	233;234;235	G;G,T;C	233;232,2;235	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4254	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2812	188.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2179	2181	CCG	235;238;239	C,G,A;C,A;G,T,C	233,1,1;237,1;237,1,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6074	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3606	210.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2552	porA	1146	1146	99.83	porA.l6.c17.ctg.1	2236	142.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	753	753	C	209	C,A	208,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	324	porB1a	984	313	90.22	porB1a.l15.c17.ctg.1	1085	29.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	797	799	AAT	2;2;2	A;A;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	324	porB1a	984	313	90.22	porB1a.l15.c17.ctg.1	1085	29.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	800	802	AAT	2;2;2	A;A;T	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	324	porB1a	984	313	90.22	porB1a.l15.c17.ctg.1	1085	29.1	0	.	p	.	0	A222V	NONSYN	664	666	GCT	812	814	GTT	2;2;3	G;T;T	2;2;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	324	porB1a	984	313	90.22	porB1a.l15.c17.ctg.1	1085	29.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	824	826	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	324	porB1a	984	313	90.22	porB1a.l15.c17.ctg.1	1085	29.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	847	849	GTA	2;2;2	G;T;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	324	porB1a	984	313	90.22	porB1a.l15.c17.ctg.1	1085	29.1	0	.	p	.	0	N237fs	FSHIFT	709	709	A	856	856	A	5	A	5	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	G38E	NONSYN	112	114	GGA	528	530	GAA	249;246;248	G,T;A;A	248,1;246;248	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	S46G	NONSYN	136	138	AGC	552	554	GGC	248;245;245	G,T;G;C,A	247,1;245;244,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	E48G	NONSYN	142	144	GAA	558	560	GGA	246;247;246	G;G,T;A,C	246;245,2;245,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	T87A	NONSYN	259	261	ACT	675	677	GCT	276;279;276	G;C;T	276;279;276	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	T89S	NONSYN	265	267	ACC	681	683	AGC	269;267;264	A,C;G;C	268,1;267;264	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	.	MULTIPLE	358	359	AA	773	774	CG	202;206	C;G,A	202;205,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	.	MULTIPLE	361	362	GA	776	778	CAG	205;206;207	C;A;G	205;206;207	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	N122K	NONSYN	364	366	AAC	780	782	AAA	206;208;210	A;A;A	206;208;210	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	K143E	NONSYN	427	429	AAA	843	845	GAA	213;213;215	G;A;A,C	213;213;214,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	V151A	NONSYN	451	453	GTA	867	869	GCA	217;219;221	G;C,A;A	217;218,1;221	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	A215T	NONSYN	643	645	GCT	1059	1061	ACT	267;266;264	A,C;C;T,G,A	266,1;266;261,2,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	I218M	NONSYN	652	654	ATA	1068	1070	ATG	260;263;259	A;T;G,T	260;263;258,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1182	1184	GCA	231;228;227	G;C;A	231;228;227	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1185	1187	ACG	228;228;225	A;C,A;G	228;227,1;225	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1188	1190	GGG	223;224;226	G;G,T;G,C	223;223,1;225,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1191	1193	GTT	224;221;222	G;T;T	224;221;222	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1251	1253	GTA	243;242;239	G;T;A	243;242;239	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1290	1292	ACT	229;229;229	A;C,T;T	229;228,1;229	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1296	1298	GAT	235;238;238	G;A;T	235;238;238	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	1	SNP	p	G120K	1	.	.	358	360	AAG	773	775	CGG	202;206;205	C;G,A;G	202;205,1;205	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	1	SNP	p	A121D	1	.	.	361	363	GAC	776	779	CGC	205;207;206	C;G;C	205;207;206	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2990	porB1b	1047	1047	97.14	porB1b.l6.c30.ctg.1	1873	196.6	1	SNP	p	D121N	0	.	.	361	363	GAC	776	779	CGC	205;207;206	C;G;C	205;207;206	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10630	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5370	246.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2217	2219	AAT	304;304;303	A;A;T	304;304;303	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1566	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1390	140.2	1	SNP	p	V57M	1	.	.	169	171	ATG	687	689	ATG	280;277;275	A;T;G	280;277;275	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
